Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2010-12-16
2011-11-22
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S120000
Reexamination Certificate
active
08063065
ABSTRACT:
Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis.Also disclosed are methods of making and methods of using same.
REFERENCES:
patent: 4999363 (1991-03-01), Oshima et al.
patent: 5118701 (1992-06-01), Oshima et al.
patent: 5242931 (1993-09-01), Oshima et al.
patent: 5302596 (1994-04-01), Oshima et al.
patent: 5534481 (1996-07-01), Suzuki et al.
patent: 5612360 (1997-03-01), Boyd et al.
patent: 5616537 (1997-04-01), Yokota et al.
patent: 5670452 (1997-09-01), Suzuki et al.
patent: 5760028 (1998-06-01), Jadhav et al.
patent: 5763616 (1998-06-01), Suzuki et al.
patent: 5770544 (1998-06-01), Yokota et al.
patent: 5973156 (1999-10-01), Chambers et al.
patent: 6025374 (2000-02-01), Castro Pineiro et al.
patent: 6107321 (2000-08-01), Madin
patent: 6211219 (2001-04-01), MacLeod et al.
patent: 6326382 (2001-12-01), Villalobos et al.
patent: 6331640 (2001-12-01), Fotouhi et al.
patent: 6498255 (2002-12-01), Villalobos et al.
patent: 6716978 (2004-04-01), Marfat
patent: 6784182 (2004-08-01), Liebeschuetz et al.
patent: 6803384 (2004-10-01), Fotouhi et al.
patent: 6855715 (2005-02-01), Liebeschuetz et al.
patent: 6878725 (2005-04-01), Liebeschuetz et al.
patent: 6900196 (2005-05-01), Liebeschuetz et al.
patent: 6936611 (2005-08-01), Liebeschuetz et al.
patent: 7049297 (2006-05-01), Zhang et al.
patent: 7053078 (2006-05-01), Liebeschuetz et al.
patent: 7129264 (2006-10-01), Smallheer et al.
patent: 7223782 (2007-05-01), Atkinson et al.
patent: 7429609 (2008-09-01), Ohi et al.
patent: 7879873 (2011-02-01), Cook et al.
patent: 2002/0037860 (2002-03-01), D'Andrea et al.
patent: 2002/0052373 (2002-05-01), Zorn et al.
patent: 2004/0127536 (2004-07-01), Bhagwat et al.
patent: 2005/0009876 (2005-01-01), Bhagwat et al.
patent: 2005/0020564 (2005-01-01), Atkinson et al.
patent: 2005/0108582 (2005-05-01), Fung
patent: 2005/0208582 (2005-09-01), Ohi et al.
patent: 2005/0261339 (2005-11-01), Ohi et al.
patent: 2006/0252781 (2006-11-01), Basarab et al.
patent: 2006/0281739 (2006-12-01), Gadek et al.
patent: 2007/0004761 (2007-01-01), Basarab et al.
patent: 2008/0262040 (2008-10-01), Callahan et al.
patent: 2009/0054397 (2009-02-01), Ohi et al.
patent: 2010/0093724 (2010-04-01), Cook et al.
patent: 2011/0034512 (2011-02-01), Disalvo et al.
patent: 2011/0086846 (2011-04-01), Cook et al.
patent: 2011/0137042 (2011-06-01), Razavi et al.
patent: 345747 (1989-12-01), None
patent: 1201268 (2002-05-01), None
patent: 10001478 (1998-01-01), None
patent: 9217475 (1992-10-01), None
patent: 9401415 (1994-01-01), None
patent: 9500509 (1995-05-01), None
patent: 9617842 (1996-06-01), None
patent: 9711945 (1997-04-01), None
patent: 9719073 (1997-05-01), None
patent: 9723480 (1997-07-01), None
patent: 9803504 (1998-01-01), None
patent: 9923076 (1999-05-01), None
patent: 0021920 (2000-04-01), None
patent: 0076970 (2000-12-01), None
patent: 0076971 (2000-12-01), None
patent: 0100656 (2001-01-01), None
patent: 0210137 (2002-02-01), None
patent: 03087085 (2003-10-01), None
patent: 03101968 (2003-12-01), None
patent: 03105853 (2003-12-01), None
patent: 2004043924 (2004-05-01), None
patent: 2004056831 (2004-07-01), None
patent: 2004094372 (2004-11-01), None
patent: 2005016929 (2005-02-01), None
patent: 2006091496 (2006-08-01), None
patent: 2006125119 (2006-11-01), None
patent: 2007002293 (2007-01-01), None
patent: 2007028083 (2007-03-01), None
patent: 2007102883 (2007-09-01), None
patent: 2008011131 (2008-01-01), None
patent: 2009024585 (2009-02-01), None
patent: 2009037570 (2009-03-01), None
patent: 2009134666 (2009-11-01), None
patent: 2009137338 (2009-11-01), None
patent: 2010036632 (2010-04-01), None
patent: 2011049917 (2011-04-01), None
patent: 2011056440 (2011-05-01), None
patent: 2011071730 (2011-06-01), None
“Alzheimer's.” Retrieved online Dec. 15, 2010. http://www.cnn.com/HEALTH/mentalhealth/alzheimers/.
Carter, P.N. et al., “N-aryl pyrazoles,indazoles and azaindazoles as antagonists of CC chemokine receptor 1: patent cooperation treaty applications WO2010036632, WO2009134666 and WO2009137337”. Expert Opinion Ther. Patents, 2010, 20(11), p. 1-10.
International Search Report for PCT/US2009/057778 mailed Jan. 11, 2010.
Conlon, K. et al., “Comparison of lymphokine secretion and mRNA expression in the CD45RA+ and CD45RO+ subsets of human peripheral blood CD4+ and CD8+ lympocytes”. European Journal of Immunology, 1995, vol. 25, p. 644-648.
Gerard, C. et al., “Chemokines and disease”. 2001 Nature Publishing Group, Chemokine Reviews, Nature Immunology, vol. 2, No. 2, Feb. 2001, p. 108-115.
Haringman, J.J. et al., “Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis”. Ann Rheum Dis, 2003, 62, p. 715-721.
Karpus, W. J. et al., “An Important Role for the Chemokine Macrophase Inflammatory Protein-1a in the Pathogenesis of the T Cell-Mediated Autoimmune Disease, Experimental Autoimmune Encephalomyelitis”. The American Association of Immunologists, 1995, p. 5003-5010.
Koch, A. E., et al., “Macrophase Inflammatory Protein-1a. A Novel Chemotactic Cytokine for Macrophages in Rheumatoid Arthritis”. The Journal of Clinical Investigation, Inc., vol. 93, Mar. 1994, p. 921-928.
Koch, A.E. et al., “Epithelial Neutrophil Activating Peptide-78: A Novel Chemotactic Cytokine for Neutrophils in Arthritis”. The Journal of Clinical Investigations, Inc. vol. 94, Sep. 1994, p. 1012-1018.
Plater-Zyberk, C. et al., “Effectof a CC chemokine receptor antagonist on collagen induced arthritis in DBA/1 mice”. Immunology Letters, 57, 1997, p. 117-120.
Revesz, L. et al., “Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis”. Bioorganice and Medicinal Chemistry Letters, 2005, p. 1-5.
Trebst, C. et al., “CCR1+/CCR5+ Mononuclear Phagocytes Accumulate in the Central Nervous System on Patients with Multiple Sclerosis.” American Journal of Pathology, vol, 159, No. 4, Nov. 2001, p. 1701-1710.
Volin, M.V. et al., “Rantes Expression and Contribution to Monocyte Chemotaxix in Arthritis”. Clinical Immunology and Immunopathology, vol. 89, No. 1, Oct. 1998, Article II984590, p. 44-53.
CAPLUS: 2009:583109, Doherty, 2009.
CAPLUS: 1990:478384, Bruneau, 1990.
CAPLUS: 2008:94643, Kitamura, 2008.
Cheng, J-F, et al., “CCR1 Antagonists”. Molecular Diversity, Kluwer Academic Publishers, vol. 12, No. 1, Jun. 17, 2008, p. 17-23.
Cook Brian Nicholas
Di Salvo Darren
Harcken Christian
Kuzmich Daniel
Lee Thomas Wai-Ho
Anderson Rebecca
Boehringer Ingelheim International GmbH
Bottino Anthony P.
Morris Michael P.
Shterengarts Samantha
LandOfFree
Azaindazole compounds as CCR1 receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azaindazole compounds as CCR1 receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azaindazole compounds as CCR1 receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4272903